Blockade of Alternative Complement Pathway in Dense Deposit Disease

A patient aged 17 with dense deposit disease associated with complement activation, circulating C3 Nef, and Factor H mutation presented with nephrotic syndrome and hypertension. Steroid therapy, plasma exchange, and rituximab failed to improve proteinuria and hypertension despite a normalization of...

Full description

Saved in:
Bibliographic Details
Main Authors: Aurore Berthe-Aucejo, Mathieu Sacquépée, Marc Fila, Michel Peuchmaur, Emilia Perrier-Cornet, Véronique Frémeaux-Bacchi, Georges Deschênes
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Case Reports in Nephrology
Online Access:http://dx.doi.org/10.1155/2014/201568
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A patient aged 17 with dense deposit disease associated with complement activation, circulating C3 Nef, and Factor H mutation presented with nephrotic syndrome and hypertension. Steroid therapy, plasma exchange, and rituximab failed to improve proteinuria and hypertension despite a normalization of the circulating sC5b9 complex. Eculizumab, a monoclonal antibody directed against C5, was used to block the terminal product of the complement cascade. The dose was adapted to achieve a CH50 below 10%, but proteinuria and blood pressure were not improved after 3 months of treatment.
ISSN:2090-6641
2090-665X